Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study
Open Access
- 18 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Pediatrics
- Vol. 20 (1), 1-8
- https://doi.org/10.1186/s12887-020-02078-w
Abstract
Background There is a limited understanding of the patient and family experience of Chronic Transfusion Therapy (CTT) for prevention of complications of Sickle Cell Disease (SCD). We sought to understand patient and family experience with CTT using qualitative methods. Methods Fifteen parents of children < 18 years old and nine children 12-18 years old with SCD who were receiving CTT for > 1 year were interviewed using a semi-structured interview format, and interviews were analyzed using open coding methods. Results Four themes created a narrative of the patient and family experience of CTT: 1) Burden of CTT, 2) Coping with CTT, 3) Perceived benefits and risks of CTT, and 4) Decision making regarding CTT. Participants reported substantial burden of CTT, including the impact of CTT on daily life and family, distress about venous access, burden of chelation therapy, and anxiety about CTT complications. Participants described how they coped with CTT. Participants reported increased energy, decreased pain, fewer hospitalizations, and stroke prevention with CTT, but also recognized complications of CTT, though awareness was limited in adolescents. Parents described sharing in the informed decision-making process with their healthcare provider about CTT, but adolescent patient participants reported that they were not involved in this process. Conclusions CTT is associated with significant patient and family burden. Support from family, healthcare providers and school may help individuals cope with some of this burden. These findings provide the basis for future studies to identify strategies to mitigate the burden of CTT and improve the patient experience with this therapy. Future studies should also systematically assess patient knowledge about the key components of CTT and chelation using quantitative assessments.Keywords
Funding Information
- American Society of Hematology
- National Heart, Lung, and Blood Institute (K23HL14014201A1)
This publication has 30 references indexed in Scilit:
- Red blood cell transfusion therapy for sickle cell patients with frequent painful eventsPediatric Blood & Cancer, 2018
- Health‐related quality of life in children with sickle cell anemia: Impact of blood transfusion therapyAmerican Journal of Hematology, 2014
- Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell AnemiaNew England Journal of Medicine, 2014
- High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donorsBlood, 2013
- Transfusion-transmitted infectionsJournal of Translational Medicine, 2007
- Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi‐center study of iron overloadAmerican Journal of Hematology, 2007
- Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final resultsBlood, 2006
- Chronic Transfusion Therapy for Children With Sickle Cell Disease and Recurrent Acute Chest SyndromeJournal of Pediatric Hematology/Oncology, 2005
- Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler UltrasonographyNew England Journal of Medicine, 1998
- Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusionsThe Journal of Pediatrics, 1995